GRAIL, Inc. $GRAL Shares Sold by Carnegie Investment Counsel

Key Points

• Carnegie Investment Counsel cut its stake in GRAIL by 13.2%, selling 32,265 shares and ending the quarter with 213,050 shares valued at about $18.24 million.
• Senior insiders executed large sales on April 8 — CEO ~123,502 shares, President 61,665 shares and CFO 45,806 shares — and insiders sold a total of 310,267 shares (~$15.49 million) over the past 90 days, a negative signal to the market.
• Shares trade well below recent highs (opened near $45.63) while analysts are mixed: average target ~$68.63 but several firms cut targets or initiated neutral/hold ratings amid a study setback and execution risks.

Carnegie Investment Counsel lowered its stake in GRAIL, Inc. (NASDAQ:GRAL - Free Report) by 13.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 213,050 shares of the company's stock after selling 32,265 shares during the period. Carnegie Investment Counsel owned 0.55% of GRAIL worth $18,235,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in GRAL. Comerica Bank raised its holdings in shares of GRAIL by 59.2% in the third quarter. Comerica Bank now owns 465 shares of the company's stock worth $27,000 after buying an additional 173 shares during the last quarter. NewEdge Advisors LLC raised its holdings in shares of GRAIL by 390.3% in the first quarter. NewEdge Advisors LLC now owns 1,760 shares of the company's stock worth $45,000 after buying an additional 1,401 shares during the last quarter. Rossby Financial LCC purchased a new position in shares of GRAIL in the third quarter worth $62,000. Atlantic Union Bankshares Corp purchased a new position in shares of GRAIL in the third quarter worth $64,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of GRAIL by 28.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company's stock worth $76,000 after buying an additional 623 shares during the last quarter.

Insider Buying and Selling

In related news, CFO Aaron Freidin sold 45,806 shares of the firm's stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the completion of the transaction, the chief financial officer owned 260,669 shares of the company's stock, valued at $13,012,596.48. This trade represents a 14.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President Joshua J. Ofman sold 61,665 shares of the firm's stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $3,078,316.80. Following the transaction, the president directly owned 371,216 shares of the company's stock, valued at approximately $18,531,102.72. This trade represents a 14.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 310,267 shares of company stock valued at $15,485,396 over the last 90 days. Insiders own 1.85% of the company's stock.

GRAIL Price Performance

Shares of GRAIL stock opened at $45.63 on Friday. The firm has a fifty day moving average price of $63.91 and a 200 day moving average price of $79.53. GRAIL, Inc. has a 1 year low of $22.30 and a 1 year high of $118.84. The stock has a market cap of $1.87 billion, a PE ratio of -4.08 and a beta of 4.62.

GRAIL (NASDAQ:GRAL - Get Free Report) last issued its earnings results on Thursday, February 19th. The company reported ($2.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.33) by $0.89. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.11%. The firm had revenue of $43.60 million during the quarter, compared to analysts' expectations of $43.33 million. As a group, equities analysts expect that GRAIL, Inc. will post -15.15 EPS for the current year.

GRAIL News Summary

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Analyst consensus remains constructive: Street coverage still shows an average rating of "Moderate Buy" with a consensus price target around $72.83, implying meaningful upside from current levels. Article Title
• Neutral Sentiment: Mizuho initiated coverage with a "neutral" rating and a $58 price target (roughly mid‑teens to low‑20s % upside vs. current quoted levels); the call is cautious and reflects uncertainty rather than outright bullishness. Article Title
• Neutral Sentiment: Piper Sandler also initiated coverage with a "neutral" rating and a $54 price target, signaling analyst caution and limited near‑term conviction. Article Title
• Negative Sentiment: Reported study setback: coverage initiation notes reference a recent study disappointment that prompted the neutral stances — clinical execution and near‑term data risk are now front and center for investors. Article Title
• Negative Sentiment: Insider selling by senior management: CEO, President and CFO sold sizable blocks on April 8 (CEO ~123,502 shares; President ~61,665; CFO ~45,806), materially reducing their holdings — a strong negative signal to the market and a likely contributor to downward pressure. Article Title

Wall Street Analysts Forecast Growth

GRAL has been the subject of a number of research analyst reports. Wall Street Zen cut shares of GRAIL from a "hold" rating to a "sell" rating in a report on Saturday. Morgan Stanley decreased their price target on shares of GRAIL from $110.00 to $60.00 and set an "equal weight" rating for the company in a report on Tuesday, February 24th. Robert W. Baird set a $82.00 price target on shares of GRAIL in a report on Friday, February 20th. Guggenheim decreased their price target on shares of GRAIL from $130.00 to $75.00 and set a "buy" rating for the company in a report on Monday, March 30th. Finally, Mizuho initiated coverage on shares of GRAIL in a report on Friday. They issued a "neutral" rating and a $58.00 price target for the company. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $68.63.

About GRAIL

GRAIL, Inc NASDAQ: GRAL is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company's platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.